Form 4: Enliven Therapeutics COO Anish Patel Reports Planned Stock Sales Under Rule 10b5-1 Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, reported planned sales of company common stock totaling 6,667 shares through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 statement.
• The filing reports sales of common stock executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• On July 7, 2025, 6,362 shares of common stock were sold at a weighted average price of $19.7483 per share.
• On the same date, an additional 305 shares of common stock were sold at a weighted average price of $20.6948 per share.
• Following these transactions, Anish Patel, through The Patel / Dong Family Trust, beneficially owns 296,642 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can sometimes be perceived negatively, the fact that these transactions are part of a pre-arranged Rule 10b5-1 plan mitigates immediate negative sentiment, suggesting personal financial planning rather than a reaction to adverse company news.

Positives

• Sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to stock disposition rather than a reaction to immediate market events.

Negatives

• A Chief Operating Officer is selling shares, which could be interpreted by some investors as a lack of confidence, although the pre-planned nature mitigates this concern.

Risks

• Potential investor perception risk due to insider stock sales, even if pre-planned, as some investors may view any insider selling negatively.

Future Outlook

The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024, indicating pre-scheduled future transactions for personal financial planning.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

Insider trading reports, such as Form 4 filings, are standard disclosures in the U.S. financial markets, providing transparency into the stock transactions of company executives and directors. These filings are closely watched by investors for insights into management's confidence and financial planning.

Comparison to Industry Standards

• Not applicable as this document reports specific insider transactions rather than company performance metrics that can be benchmarked against industry peers.

Related Party Transactions

• The shares sold are held by The Patel / Dong Family Trust, for which Anish Patel serves as trustee, indicating a related party transaction.

Stakeholder Impact

• Shareholders may interpret the sales as a signal regarding management's view of the company, though the context of a Rule 10b5-1 plan suggests personal financial planning rather than a direct reflection of company performance.

Next Steps

• The Rule 10b5-1 trading plan, adopted on September 30, 2024, may involve further pre-scheduled transactions by the Reporting Person.

Key Dates

Recommendation

Keywords

Enliven Therapeutics, ELVN, Anish Patel, Form 4, SEC filing, insider trading, stock sale, Rule 10b5-1, Chief Operating Officer, common stock